UniSA Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, 5000, Australia.
Drug Deliv Transl Res. 2023 Jun;13(6):1716-1729. doi: 10.1007/s13346-022-01287-3. Epub 2023 Jan 11.
Intracellular bacteria serve as a problematic source of infection due to their ability to evade biological immune responses and the inability for conventional antibiotics to efficiently penetrate cellular membranes. Subsequently, new treatment approaches are urgently required to effectively eradicate intracellular pathogens residing within immune cells (e.g. macrophages). In this study, the poorly soluble and poorly permeable antibiotic, rifampicin, was re-purposed via micro-encapsulation within inulin-lipid hybrid (ILH) particles for the treatment of macrophages infected with small colony variants of Staphylococcus aureus (SCV S. aureus). Rifampicin-encapsulated ILH (Rif-ILH) microparticles were synthesized by spray drying a lipid nano-emulsion, with inulin dissolved throughout the aqueous phase and rifampicin pre-loaded within the lipid phase. Rif-ILH were strategically designed and engineered with pH-responsive properties to promote lysosomal drug release upon cellular internalization, while preventing premature rifampicin release in plasma-simulating media. The pH-responsiveness of Rif-ILH was controlled by the acid-mediated hydrolysis of the inulin coating, where exposure to acidic media simulating the lysosomal environment of macrophages triggered hydrolysis of the oligofructose chain and the subsequent diffusion of rifampicin from Rif-ILH. This pH-provoked release mechanism, as well as the ability for ILH microparticles to be more readily internalized by macrophages, was found to be influential in triggering a 2.9-fold increase in intracellular rifampicin concentration within infected macrophages, compared to the pure drug. The subsequent increase in exposure of intracellular pathogens to rifampicin leads to a ~ 2-log improvement in antibacterial activity for Rif-ILH, at a rifampicin dose of 2.5 µg/mL. Thus, the reduction in viability of intracellular SCV S. aureus, in the absence of cellular toxicity, is indicative of ILH microparticles serving as a unique approach for the safe and efficacious delivery of antibiotics to phagocytic cells for the treatment of intracellular infections.
细胞内细菌能够逃避生物免疫反应,并且常规抗生素难以有效穿透细胞膜,因此成为了一个有问题的感染源。因此,迫切需要新的治疗方法来有效清除存在于免疫细胞(如巨噬细胞)内的细胞内病原体。在这项研究中,将疏水性和低渗透性的抗生素利福平通过包封在菊粉-脂质杂化(ILH)颗粒内重新用于治疗感染金黄色葡萄球菌小菌落变异体(SCV S. aureus)的巨噬细胞。利福平包封的 ILH(Rif-ILH)微球是通过喷雾干燥脂质纳米乳液合成的,其中菊粉溶解在整个水相中,利福平预先加载在脂质相中。Rif-ILH 被设计和构建为具有 pH 响应特性,以促进细胞内化时溶酶体药物释放,同时防止在模拟血浆的介质中过早释放利福平。Rif-ILH 的 pH 响应性由菊粉涂层的酸介导水解控制,其中暴露于模拟巨噬细胞溶酶体环境的酸性介质中会触发低聚果糖链的水解,随后利福平从 Rif-ILH 中扩散。这种 pH 触发的释放机制,以及 ILH 微球更易被巨噬细胞内化的能力,被发现能够在感染的巨噬细胞中引发细胞内利福平浓度增加 2.9 倍,与纯药物相比。细胞内病原体暴露于利福平的增加导致 Rif-ILH 的抗菌活性提高了约 2 个对数级,在 2.5μg/mL 的利福平剂量下。因此,在没有细胞毒性的情况下,细胞内 SCV S. aureus 的活力降低表明,ILH 微球是一种将抗生素安全有效地递送至吞噬细胞以治疗细胞内感染的独特方法。